{
    "clinical_study": {
        "@rank": "40175", 
        "arm_group": {
            "arm_group_label": "Cetaphil Moisturizing Lotion Daily Advance", 
            "arm_group_type": "Experimental", 
            "description": "Each subject had Cetaphil Moisturizing Lotion Daily Advance applied"
        }, 
        "brief_summary": {
            "textblock": "Human repeat insult patch test to assess the potential for Cetaphil Moisturizing Lotion\n      Daily Advance to induce sensitization to the skin"
        }, 
        "brief_title": "Repeat Insult Patch Test for Daily Advance Cetaphil Moisturizing Lotion", 
        "condition": "Skin Irritation", 
        "eligibility": {
            "criteria": {
                "textblock": "Inclusion Criteria:\n\n          -  Age 18-65 years\n\n          -  Good health\n\n          -  willingness to cooperate and participate\n\n          -  willingness to avoid topical products at test sites\n\n          -  willingness to avoid direct sun exposure to test sites\n\n        Exclusion Criteria:\n\n          -  Individuals with active psoriasis or eczema\n\n          -  individuals with sunburn, acne, abrasions, scar tissue, or tattoos on test sites, or\n             disease of skin that might interfere\n\n          -  individuals who have had a mastectomy with axillary nodes were removed\n\n          -  individuals receiving anticancer, immunosuppressive treatments or medications, or\n             radiation\n\n          -  pregnant, nursing, or planned to become pregnant\n\n          -  use of topical steroids or drugs at test sites\n\n          -  active or untreated skin cancer\n\n          -  active hepatitis\n\n          -  current routine or frequent use of high doses of anti-inflammatory drugs\n\n          -  individuals who have had les than two week rest period since completion of previous\n             patch testing on upper back or upper arms\n\n          -  individuals with uncontrolled metabolic diseases"
            }, 
            "gender": "Both", 
            "healthy_volunteers": "Accepts Healthy Volunteers", 
            "maximum_age": "65 Years", 
            "minimum_age": "18 Years"
        }, 
        "enrollment": {
            "#text": "146", 
            "@type": "Actual"
        }, 
        "firstreceived_date": "June 26, 2013", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT01892423", 
            "org_study_id": "GLI.04SPR.US10044"
        }, 
        "intervention": {
            "arm_group_label": "Cetaphil Moisturizing Lotion Daily Advance", 
            "intervention_name": "Cetaphil Moisturizing Lotion Daily Advance", 
            "intervention_type": "Other"
        }, 
        "intervention_browse": {
            "mesh_term": "Emollients"
        }, 
        "is_fda_regulated": "No", 
        "lastchanged_date": "July 1, 2013", 
        "location": {
            "facility": {
                "address": {
                    "city": "Carrollton", 
                    "country": "United States", 
                    "state": "Texas", 
                    "zip": "75006"
                }, 
                "name": "Thomas J Stephens and Associates Inc"
            }
        }, 
        "location_countries": {
            "country": "United States"
        }, 
        "number_of_arms": "1", 
        "official_title": "Daily Advance Cetaphil Moisturizing Lotion: Human Repeat Insult Patch Test", 
        "overall_official": {
            "last_name": "James H Herndon, MD, FAAD", 
            "role": "Principal Investigator"
        }, 
        "overall_status": "Completed", 
        "oversight_info": {
            "authority": "United States: Food and Drug Administration", 
            "has_dmc": "No"
        }, 
        "phase": "N/A", 
        "primary_completion_date": {
            "#text": "September 2006", 
            "@type": "Actual"
        }, 
        "primary_outcome": {
            "description": "all patients will be assessed at 14 visits for redness (erythema), spreading, weeping, papules, vesicles, and bullae at application site", 
            "measure": "Irritation responses", 
            "safety_issue": "No", 
            "time_frame": "average of 5 weeks"
        }, 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT01892423"
        }, 
        "responsible_party": {
            "responsible_party_type": "Sponsor"
        }, 
        "source": "Galderma Laboratories, L.P.", 
        "sponsors": {
            "lead_sponsor": {
                "agency": "Galderma Laboratories, L.P.", 
                "agency_class": "Industry"
            }
        }, 
        "start_date": "August 2006", 
        "study_design": "Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Supportive Care", 
        "study_type": "Interventional", 
        "verification_date": "June 2013"
    }
}